Cancer Discovery

Article	Citations
Hallmarks of Cancer: New Dimensions	4348
Therapeutic Targeting of the Tumor Microenvironment	797
Liquid Biopsy: From Discovery to Clinical Application	502
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors	459
The Next Decade of Immune Checkpoint Therapy	445
Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level	419
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab	294
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation	284
Artificial Intelligence in Cancer Research and Precision Medicine	278
Tumor-Infiltrating Natural Killer Cells	267
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition	256
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells	244
Diffuse Glioma Heterogeneity and Its Therapeutic Implications	237
Paradigms on Immunotherapy Combinations with Chemotherapy	237
Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer	233
Modes of Regulated Cell Death in Cancer	226
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade	196
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy	189
Metastasis-Initiating Cells and Ecosystems	181
Metabolic Codependencies in the Tumor Microenvironment	179
Development of Immunotherapy Combination Strategies in Cancer	173
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention	172
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib	171
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial	168
Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy	168

Lower Airway Dysbiosis Affects Lung Cancer Progression	164
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis	164
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited	163
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer	162
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors	157
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study	157
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma	156
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers	153
Targeting the p300/CBP Axis in Lethal Prostate Cancer	150
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response	149
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer	149
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence	149
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer	145
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease	143
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer	139
Independent Drug Action in Combination Therapy: Implications for Precision Oncology	138
Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer	137
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies	137
WNT as a Driver and Dependency in Cancer	136
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma	136
The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis	135
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets	135
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures	135
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants	135
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade	134
St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem	134
Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer	129
Mobocertinib (TAK-788): A Targeted Inhibitor ofEGFRExon 20 Insertion Mutants in Non–Small Cell Lung Cancer	121
Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer–Associated Fibroblasts	117
Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast–Driven Nutritional Support and Immunosuppression	116
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing	114
Synthetic Lethality in Cancer Therapeutics: The Next Generation	114
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab	112
The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution	112
Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity	112
Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic	111
Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors	111
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity	109
A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota	108
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells	107
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer	106
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy	104
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy	104
A Procarcinogenic Colon Microbe Promotes Breast Tumorigenesis and Metastatic Progression and Concomitantly Activates Notch and β-Catenin Axes	104
Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy	101
Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy	100
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative	100
Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety	100
Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia	99
Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity	98

A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy	98
IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity	98
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition	98
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?	96
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome	95
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial	95
IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment	94
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia	94
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma	92
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies	92
A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation	92
A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era	91
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders	91
CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies	91
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia	91
Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis	90
Tracking Cancer Evolution through the Disease Course	90
Tumor Immunity and Immunotherapy for HPV-Related Cancers	88
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma	88
Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis	87
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer	87
Direct and Indirect Regulators of Epithelial–Mesenchymal Transition–Mediated Immunosuppression in Breast Carcinomas	86
The Complex Integration of T-cell Metabolism and Immunotherapy	85
NRF2: KEAPing Tumors Protected	85
Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers	85
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade	84
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors	84
Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer	84
An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants	83
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements	82
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity	82
Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations	81
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade	81
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution	81
Next-Generation CAR T-cell Therapies	80
Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer	80
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing	79
Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation	78
Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation	78
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression	77
Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer	76
Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin	75
Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies	74
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis	73
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy	73
Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma	73
PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity	71
Mechanisms of Resistance to KRASG12C-Targeted Therapy	71
Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site	70
Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System	70
CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory	70
Redox Regulation in Cancer Cells during Metastasis	70
NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron–Sulfur Cluster Proteins	69
Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation	69
African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent	68
The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes	68
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C	68
Cell of Origin Influences Pancreatic Cancer Subtype	67
DietaryLactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy	67
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo	64
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor	64
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies	64
Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches	63
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions	63
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC	62
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma	62
TargetingEGFRExon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates	61
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients	61
Detecting Liver Cancer Using Cell-Free DNA Fragmentomes	61
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer	60
Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung	59
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy	59
C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan	58
Macropinocytosis in Cancer-Associated Fibroblasts Is Dependent on CaMKK2/ARHGEF2 Signaling and Functions to Support Tumor and Stromal Cell Fitness	58
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly EffectiveIn Vivowithout Systemic Immune Activation	57
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer	57
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON	57
ZFTA–RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma	57
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC	56
Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma	56

Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing	55
Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation	55
Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy	55
The Cancer Microbiome: Recent Highlights and Knowledge Gaps	55
FGFR2Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma	55
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer	54
Human Colon Cancer–Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice	54
CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells	53
The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma	53
DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells	53
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer	52
Bacterial-Driven Inflammation and Mutant BRAF Expression Combine to Promote Murine Colon Tumorigenesis That Is Sensitive to Immune Checkpoint Therapy	52
Sex-BiasedZRSR2Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis	52
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN	51
Obesity-Dependent Adipokine Chemerin Suppresses Fatty Acid Oxidation to Confer Ferroptosis Resistance	51
H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone	51
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors	51
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease	51
Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes	50
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown	50
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity	50
Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia	50
Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise—Evidence and Implications	49
Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies	49
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain	48
MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression	48
Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages	48
Reprogrammed Schwann Cells Organize into Dynamic Tracks that Promote Pancreatic Cancer Invasion	48
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma	47
MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma	47
Discovery of Candidate DNA Methylation Cancer Driver Genes	47
Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells	47
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease	47
Discovery and Features of an Alkylating Signature in Colorectal Cancer	47
Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti–PD-1 Treatment	47
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma	46
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy	46
Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis	46
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study	45
Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors	45
Distinct Tumor Necrosis Factor Alpha Receptors Dictate Stem Cell Fitness versus Lineage Output in Dnmt3a-Mutant Clonal Hematopoiesis	45
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	45
Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL	44
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer	44
Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1	44
AACR Project GENIE: 100,000 Cases and Beyond	44
KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs	44
Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma	44
Classification ofKRAS-Activating Mutations and the Implications for Therapeutic Intervention	44
Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy	44
The Future of Clinical Trial Design in Oncology	43
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis	43
CD4 T Cell–Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair–Deficient Tumors	43
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death	43
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon	43
Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma	43
A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung Cancer	42
Decoding Cancer Biology One Cell at a Time	42
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways	42
Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells	42
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant inPIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers	42
Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas	42
MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING	42
A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function	42
Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer	42
Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS–MAPK Pathway Inhibition in Pancreatic Cancer	42
Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia	42
AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B	41
Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor	41
Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer	41
ZFTATranslocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors	40
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer	40
Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling	40
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors	40
Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis	40
An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML	39
Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy	39
Clonal Hematopoiesis: From Mechanisms to Clinical Intervention	39
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth	39
Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer	39
Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade	39
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma	39
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma	39
Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma	39
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade	39
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating	38
Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History	38
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability	38
Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer	38
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations	38
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer	38
Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer	38
Mapping Phenotypic Plasticity upon the Cancer Cell State Landscape Using Manifold Learning	37
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes	37
Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer	37